{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T18:23:16Z","timestamp":1771611796547,"version":"3.50.1"},"reference-count":118,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2010,10,1]],"date-time":"2010-10-01T00:00:00Z","timestamp":1285891200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,12,7]],"date-time":"2015-12-07T00:00:00Z","timestamp":1449446400000},"content-version":"vor","delay-in-days":1893,"URL":"https:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Kidney International"],"published-print":{"date-parts":[[2010,10]]},"DOI":"10.1038\/ki.2010.292","type":"journal-article","created":{"date-parts":[[2010,8,18]],"date-time":"2010-08-18T13:37:00Z","timestamp":1282138620000},"page":"726-736","source":"Crossref","is-referenced-by-count":41,"title":["National Kidney Foundation consensus conference on cardiovascular and kidney diseases and diabetes risk: an integrated therapeutic approach to reduce events"],"prefix":"10.1016","volume":"78","author":[{"given":"George","family":"Bakris","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph","family":"Vassalotti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eberhard","family":"Ritz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christoph","family":"Wanner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"George","family":"Stergiou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark","family":"Molitch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard","family":"Nesto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"George A.","family":"Kaysen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James R.","family":"Sowers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1038\/ki.2010.292_bb0010","doi-asserted-by":"crossref","first-page":"2560","DOI":"10.1001\/jama.289.19.2560","article-title":"The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report","volume":"289","author":"Chobanian","year":"2003","journal-title":"JAMA"},{"issue":"suppl 1","key":"10.1038\/ki.2010.292_bb0015","first-page":"S1","article-title":"KDOQI Clinical Practice Guidelines on Hypertension and Antihypertensive Agents in Chronic Kidney Disease","volume":"43","author":"National Kidney Foundation","year":"2004","journal-title":"Am J Kidney Dis"},{"issue":"Suppl 1","key":"10.1038\/ki.2010.292_bb0020","first-page":"S1","article-title":"Standards of medical care in diabetes","volume":"33","author":"American Diabetes Association","year":"2010","journal-title":"Diabetes Care"},{"key":"10.1038\/ki.2010.292_bb0025","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1016\/S0140-6736(02)11911-8","article-title":"Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies","volume":"360","author":"Lewington","year":"2002","journal-title":"Lancet"},{"key":"10.1038\/ki.2010.292_bb0030","doi-asserted-by":"crossref","first-page":"2421","DOI":"10.1001\/jama.288.19.2421","article-title":"Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial","volume":"288","author":"Wright","year":"2002","journal-title":"JAMA"},{"key":"10.1038\/ki.2010.292_bb0035","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/S0140-6736(05)71082-5","article-title":"Blood-pressure control for renoprotection in patients with non-diabetic chronic renal disease (REIN-2): multicentre, randomised controlled trial","volume":"365","author":"Ruggenenti","year":"2005","journal-title":"Lancet"},{"key":"10.1038\/ki.2010.292_bb0040","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1056\/NEJMoa1001286","article-title":"Effects of intensive blood-pressure control in type 2 diabetes mellitus","volume":"362","author":"ACCORD Study GroupCushman","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1038\/ki.2010.292_bb0045","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1053\/j.ajkd.2009.04.029","article-title":"Proteinuria as a surrogate outcome in CKD: report of a scientific workshop sponsored by the National Kidney Foundation and the US Food and Drug Administration","volume":"54","author":"Levey","year":"2009","journal-title":"Am J Kidney Dis"},{"key":"10.1038\/ki.2010.292_bb0050","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.jash.2010.03.003","article-title":"When and how to use self (home) and ambulatory blood pressure monitoring","volume":"4","author":"Pickering","year":"2010","journal-title":"J Am Soc Hypertens"},{"key":"10.1038\/ki.2010.292_bb0055","doi-asserted-by":"crossref","first-page":"3089","DOI":"10.1093\/ndt\/gfm419","article-title":"Home BP for assessing haemodialysis hypertension","volume":"22","author":"Agarwal","year":"2007","journal-title":"Nephrol Dial Transplant"},{"key":"10.1038\/ki.2010.292_bb0060","doi-asserted-by":"crossref","first-page":"656","DOI":"10.2215\/CJN.05391008","article-title":"Masked hypertension and white-coat hypertension in chronic kidney disease: a meta-analysis","volume":"4","author":"Bangash","year":"2009","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1038\/ki.2010.292_rf0065","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1159\/000097366","article-title":"Blood pressure recordings within and outside the clinic and cardiovascular events in chronic kidney disease","volume":"26","author":"Agarwal","year":"2006","journal-title":"Am J Nephrol"},{"key":"10.1038\/ki.2010.292_bb0070","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1038\/sj.ki.5000081","article-title":"Prognostic importance of clinic and home blood pressure recordings in patients with chronic kidney disease","volume":"69","author":"Agarwal","year":"2006","journal-title":"Kidney Int"},{"key":"10.1038\/ki.2010.292_bb0075","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1053\/ajkd.2000.16225","article-title":"Preserving renal function in adults with hypertension and diabetes: a consensus approach. National Kidney Foundation Hypertension and Diabetes Executive Committees Working Group","volume":"36","author":"Bakris","year":"2000","journal-title":"Am J Kidney Dis"},{"key":"10.1038\/ki.2010.292_bb0080","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1001\/archinte.160.5.685","article-title":"Angiotensin-converting enzyme inhibitor-associated elevations in serum creatinine: is this a cause for concern?","volume":"160","author":"Bakris","year":"2000","journal-title":"Arch Intern Med"},{"key":"10.1038\/ki.2010.292_bb0085","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.semnephrol.2003.11.001","article-title":"Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in chronic renal disease: safety issues","volume":"24","author":"Mangrum","year":"2004","journal-title":"Semin Nephrol"},{"key":"10.1038\/ki.2010.292_bb0090","doi-asserted-by":"crossref","first-page":"2254","DOI":"10.1046\/j.1523-1755.2003.00033.x","article-title":"Retarding progression of chronic renal disease: the neglected issue of residual proteinuria","volume":"63","author":"Ruggenenti","year":"2003","journal-title":"Kidney Int"},{"key":"10.1038\/ki.2010.292_bb0095","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1159\/000093833","article-title":"An in-depth review of the evidence linking dietary salt intake and progression of chronic kidney disease","volume":"26","author":"Jones-Burton","year":"2006","journal-title":"Am J Nephrol"},{"key":"10.1038\/ki.2010.292_bb0100","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1097\/MNH.0b013e32832edc99","article-title":"Should proteinuria reduction be the criterion for antihypertensive drug selection for patients with kidney disease?","volume":"18","author":"Kalaitzidis","year":"2009","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"10.1038\/ki.2010.292_bb0105","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1001\/archinte.165.8.947","article-title":"The relationship between magnitude of proteinuria reduction and risk of end-stage renal disease: results of the African American study of kidney disease and hypertension","volume":"165","author":"Lea","year":"2005","journal-title":"Arch Intern Med"},{"key":"10.1038\/ki.2010.292_bb0110","doi-asserted-by":"crossref","first-page":"1991","DOI":"10.1111\/j.1523-1755.2004.00620.x","article-title":"Differential effects of calcium antagonist subclasses on markers of nephropathy progression","volume":"65","author":"Bakris","year":"2004","journal-title":"Kidney Int"},{"key":"10.1038\/ki.2010.292_bb0115","doi-asserted-by":"crossref","first-page":"30","DOI":"10.7326\/0003-4819-148-1-200801010-00190","article-title":"Meta-analysis: effect of monotherapy and combination therapy with inhibitors of the renin angiotensin system on proteinuria in renal disease","volume":"148","author":"Kunz","year":"2008","journal-title":"Ann Intern Med"},{"key":"10.1038\/ki.2010.292_bb0120","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/S0140-6736(08)61236-2","article-title":"Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial","volume":"372","author":"Mann","year":"2008","journal-title":"Lancet"},{"key":"10.1038\/ki.2010.292_bb0125","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/S0140-6736(08)61212-X","article-title":"Renin-angiotensin blockade and kidney disease","volume":"372","author":"Sarafidis","year":"2008","journal-title":"Lancet"},{"key":"10.1038\/ki.2010.292_bb0130","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1053\/j.ajkd.2007.10.040","article-title":"Change in proteinuria after adding aldosterone blockers to ACE inhibitors or angiotensin receptor blockers in CKD: a systematic review","volume":"51","author":"Bomback","year":"2008","journal-title":"Am J Kidney Dis"},{"key":"10.1038\/ki.2010.292_bb0135","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1159\/000237742","article-title":"Predictors of hyperkalemia risk following hypertension control with aldosterone blockade","volume":"30","author":"Khosla","year":"2009","journal-title":"Am J Nephrol"},{"key":"10.1038\/ki.2010.292_bb0140","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.1056\/NEJMoa0708379","article-title":"Aliskiren combined with losartan in type 2 diabetes and nephropathy","volume":"358","author":"Parving","year":"2008","journal-title":"N Engl J Med"},{"issue":"Suppl 3","key":"10.1038\/ki.2010.292_bb0145","first-page":"S1","article-title":"K\/DOQI Clinical Practice Guidelines for management of dyslipidemias in patients with kidney disease","volume":"41","author":"National Kidney Foundation","year":"2003","journal-title":"Am J Kidney Dis"},{"issue":"Suppl 2","key":"10.1038\/ki.2010.292_bb0150","first-page":"S1","article-title":"KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for diabetes and chronic kidney disease","volume":"49","author":"National Kidney Foundation","year":"2007","journal-title":"Am J Kidney Dis"},{"key":"10.1038\/ki.2010.292_bb0155","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1161\/01.CIR.0000133317.49796.0E","article-title":"Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines","volume":"110","author":"Grundy","year":"2004","journal-title":"Circulation"},{"key":"10.1038\/ki.2010.292_bb0160","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1093\/oxfordjournals.aje.a113348","article-title":"Plasma lipids and diabetes mellitus in an adult community","volume":"115","author":"Barrett-Connor","year":"1982","journal-title":"Am J Epidemiol"},{"key":"10.1038\/ki.2010.292_bb0165","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1161\/01.ATV.12.12.1496","article-title":"LDL subclass phenotypes and triglyceride metabolism in non-insulin-dependent diabetes","volume":"12","author":"Feingold","year":"1992","journal-title":"Arterioscler Thromb"},{"key":"10.1038\/ki.2010.292_bb0170","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1046\/j.1523-1755.2003.00164.x","article-title":"Lipoproteins in the DCCT\/EDIC cohort: associations with diabetic nephropathy","volume":"64","author":"Jenkins","year":"2003","journal-title":"Kidney Int"},{"key":"10.1038\/ki.2010.292_bb0175","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1681\/ASN.V102332","article-title":"Noninsulin-dependent diabetes mellitus and hypertriglyceridemia impair lipoprotein metabolism in chronic hemodialysis patients","volume":"10","author":"Quaschning","year":"1999","journal-title":"J Am Soc Nephrol"},{"key":"10.1038\/ki.2010.292_bb0180","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.1016\/j.jacc.2008.02.034","article-title":"Lipoprotein management in patients with cardiometabolic risk: consensus conference report from the American Diabetes Association and the American College of Cardiology Foundation","volume":"51","author":"Brunzell","year":"2008","journal-title":"J Am Coll Cardiol"},{"key":"10.1038\/ki.2010.292_bb0185","doi-asserted-by":"crossref","first-page":"2542","DOI":"10.1001\/jama.287.19.2542","article-title":"Cost-effectiveness of intensive glycemic control, intensified hypertension control, and serum cholesterol level reduction for type 2 diabetes","volume":"287","author":"The CDC Diabetes Cost-effectiveness Group","year":"2002","journal-title":"JAMA"},{"key":"10.1038\/ki.2010.292_bb0190","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1097\/01.mol.0000137219.31407.16","article-title":"Cardiovascular outcomes among participants with diabetes in the recent large statin trials","volume":"15","author":"Armitage","year":"2004","journal-title":"Curr Opin Lipidol"},{"key":"10.1038\/ki.2010.292_bb0195","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1111\/j.1365-2125.2003.02060.x","article-title":"Meta-analysis of large randomized controlled trials to evaluate the impact of statins on cardiovascular outcomes","volume":"57","author":"Cheung","year":"2004","journal-title":"Br J Clin Pharmacol"},{"key":"10.1038\/ki.2010.292_bb0200","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/S0140-6736(04)16895-5","article-title":"Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): Multicentre randomised placebocontrolled trial","volume":"364","author":"Colhoun","year":"2004","journal-title":"Lancet"},{"key":"10.1038\/ki.2010.292_bb0205","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/S0140-6736(02)09327-3","article-title":"MRC\/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial","volume":"360","author":"Heart Protection Study Collaborative Group","year":"2002","journal-title":"Lancet"},{"key":"10.1038\/ki.2010.292_bb0210","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1161\/01.CIR.0000143892.84582.60","article-title":"Effect of pravastatin on cardiovascular events in people with chronic kidney disease","volume":"110","author":"Tonelli","year":"2004","journal-title":"Circulation"},{"key":"10.1038\/ki.2010.292_bb0215","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.2215\/CJN.04371206","article-title":"Effect of intensive lipid lowering with atorvastatin on renal function in patients with coronary heart disease: the Treating to New Targets (TNT) study","volume":"2","author":"Shepherd","year":"2007","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1038\/ki.2010.292_bb0220","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1016\/j.jacc.2007.11.072","article-title":"Intensive lipid lowering with atorvastatin in patients with coronary heart disease and chronic kidney disease: the TNT (Treating to New Targets) study","volume":"51","author":"Shepherd","year":"2008","journal-title":"J Am Coll Cardiol"},{"key":"10.1038\/ki.2010.292_bb0225","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1016\/j.jacc.2010.01.020","volume":"55","author":"Ridker","year":"2010","journal-title":"J Am Coll Cardiol"},{"key":"10.1038\/ki.2010.292_bb0230","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1056\/NEJMoa043545","article-title":"Atorvatatin in patients with type 2 diabetes mellitus undergoing hemodialysis","volume":"353","author":"Wanner","year":"2005","journal-title":"New Engl J Med"},{"key":"10.1038\/ki.2010.292_bb0235","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1056\/NEJMoa0810177","article-title":"Rosuvastatin and cardiovascular events in patients undergoing hemodialysis","volume":"360","author":"Fellstr\u00f6m","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1038\/ki.2010.292_bb0240","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.2337\/diacare.26.5.1402","article-title":"Analysis of metabolic parameters as predictors of risk in the RENAAL study","volume":"26","author":"Appel","year":"2003","journal-title":"Diabetes Care"},{"key":"10.1038\/ki.2010.292_bb0245","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1007\/BF02342442","article-title":"Plasma lipoproteins and renal function during simvastatin treatment in diabetic nephropathy","volume":"35","author":"Hommel","year":"1992","journal-title":"Diabetologia"},{"key":"10.1038\/ki.2010.292_bb0250","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1159\/000046648","article-title":"Effect of cerivastatin on urinary albumin excretion and plasma endothelin-1 concentrations in type 2 diabetes patients with microalbuminuria and dyslipidemia","volume":"21","author":"Nakamura","year":"2001","journal-title":"Am J Nephrol"},{"key":"10.1038\/ki.2010.292_bb0255","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1007\/BF00400731","article-title":"Cholesterol- lowering therapy may retard the progression of diabetic nephropathy","volume":"38","author":"Lam","year":"1995","journal-title":"Diabetologia"},{"key":"10.1038\/ki.2010.292_bb0260","doi-asserted-by":"crossref","first-page":"91","DOI":"10.5551\/jat1994.7.91","article-title":"Effect of bezafibrate or pravastatin on serum lipid levels and albuminuria in NIDDM patients","volume":"7","author":"Nagai","year":"2000","journal-title":"J Atheroscler Thromb"},{"key":"10.1038\/ki.2010.292_bb0265","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1046\/j.1365-2362.2000.00735.x","article-title":"Additive effects of simvastatin beyond its effects on LDL cholesterol in hypertensive type 2 diabetic patients","volume":"30","author":"Tonolo","year":"2000","journal-title":"Eur J Clin Invest"},{"key":"10.1038\/ki.2010.292_bb0270","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1007\/BF02374502","article-title":"Renal function and insulin sensitivity during simvastatin treatment in type 2 (non-insulin-dependent) diabetic patients with microalbuminuria","volume":"36","author":"Nielsen","year":"1993","journal-title":"Diabetologia"},{"key":"10.1038\/ki.2010.292_bb0275","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1046\/j.1365-2362.1997.2330779.x","article-title":"Can reduction in hypertriglyceridaemia slow progression of microalbuminuria in patients with non-insulin-dependent diabetes mellitus?","volume":"27","author":"Smulders","year":"1997","journal-title":"Eur J Clin Invest"},{"key":"10.1038\/ki.2010.292_bb0280","doi-asserted-by":"crossref","first-page":"858","DOI":"10.7326\/0003-4819-150-12-200906160-00009","article-title":"Narrative review: statin-related myopathy","volume":"150","author":"Joy","year":"2009","journal-title":"Ann Intern Med"},{"key":"10.1038\/ki.2010.292_bb0285","first-page":"CD007784","article-title":"HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis","volume":"2","author":"Navaneethan","year":"2009","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1038\/ki.2010.292_bb0290","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1053\/j.ajkd.2005.11.018","article-title":"The second United Kingdom Heart and Renal Protection (UK-HARP II) study: a randomized controlled study of biochemical safety and efficacy of adding ezetimibe to simvastatin as initial therapy among patients with CKD","volume":"47","author":"Landray","year":"2006","journal-title":"Am J Kidney Dis"},{"issue":"Suppl","key":"10.1038\/ki.2010.292_rf0295","doi-asserted-by":"crossref","first-page":"S207","DOI":"10.1046\/j.1523-1755.63.s84.4.x","article-title":"Study of Heart and Renal Protection (SHARP)","volume":"84","author":"Baigent","year":"2003","journal-title":"Kidney Int"},{"key":"10.1038\/ki.2010.292_bb0300","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1056\/NEJMoa1001282","article-title":"Effects of combination lipid therapy in type 2 diabetes mellitus","volume":"362","author":"ACCORD Study GroupGinsberg","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1038\/ki.2010.292_bb0305","doi-asserted-by":"crossref","first-page":"434","DOI":"10.2337\/diacare.16.2.434","article-title":"Diabetes, other risk factors and 12-year cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial","volume":"16","author":"Stamler","year":"1993","journal-title":"Diabetes Care"},{"key":"10.1038\/ki.2010.292_bb0310","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1056\/NEJM199807233390404","article-title":"Mortality from coronary heart disease in subjects with type 2 Diabetes Mellitus in patients with myocardial infarction and in non\u2013diabetic subjects with and without prior history of myocardial infarction","volume":"339","author":"Haffner","year":"1998","journal-title":"N Engl J Med"},{"key":"10.1038\/ki.2010.292_bb0315","doi-asserted-by":"crossref","first-page":"2046","DOI":"10.2337\/dc06-0248","article-title":"Glomerular filtration rate, cardiorenal end points, and all-cause mortality in type 2 diabetic patients","volume":"29","author":"So","year":"2006","journal-title":"Diabetes Care"},{"key":"10.1038\/ki.2010.292_bb0320","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1056\/NEJM199309303291401","article-title":"The Diabetes Control and Complications Trial Research Group: the effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus","volume":"329","year":"1993","journal-title":"N Engl J Med"},{"key":"10.1038\/ki.2010.292_bb0325","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/S0140-6736(98)07019-6","article-title":"Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)","volume":"352","author":"UK Prospective Diabetes Study (UKPDS) Group","year":"1998","journal-title":"Lancet"},{"key":"10.1038\/ki.2010.292_bb0330","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1016\/S0140-6736(98)07037-8","article-title":"Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34)","volume":"352","author":"UK Prospective Diabetes Study (UKPDS) Group","year":"1998","journal-title":"Lancet"},{"issue":"Suppl 2","key":"10.1038\/ki.2010.292_bb0335","first-page":"B21","article-title":"Long-term results of the Kumamoto Study on optimal diabetes control in type2 diabetic patients","volume":"23","author":"Shichiri","year":"2000","journal-title":"Diabetes Care"},{"key":"10.1038\/ki.2010.292_bb0340","doi-asserted-by":"crossref","first-page":"2560","DOI":"10.1056\/NEJMoa0802987","article-title":"Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes","volume":"358","author":"ADVANCE Collaborative GroupPatel","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1038\/ki.2010.292_bb0345","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.1111\/j.1523-1755.2004.00925.x","article-title":"Progression of nephropathy in type 2 diabetic patients","volume":"66","author":"Rossing","year":"2004","journal-title":"Kidney Int"},{"key":"10.1038\/ki.2010.292_bb0350","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1046\/j.1523-1755.2001.059002702.x","article-title":"Progression of diabetic nephropathy","volume":"59","author":"Hovind","year":"2001","journal-title":"Kidney Int"},{"issue":"Suppl 2","key":"10.1038\/ki.2010.292_bb0355","doi-asserted-by":"crossref","first-page":"S86","DOI":"10.1681\/ASN.2005121343","article-title":"Renal protection in diabetes: role of glycemic control","volume":"17","author":"Fioretto","year":"2006","journal-title":"J Am Soc Nephrol"},{"key":"10.1038\/ki.2010.292_bb0360","doi-asserted-by":"crossref","first-page":"3411","DOI":"10.1681\/ASN.2005050552","article-title":"Glycosylated hemoglobin and mortality in patients with nondiabetic chronic kidney disease","volume":"16","author":"Menon","year":"2005","journal-title":"J Am Soc Nephrol"},{"key":"10.1038\/ki.2010.292_bb0365","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/0168-8227(95)01064-K","article-title":"Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study","volume":"28","author":"Ohkubo","year":"1995","journal-title":"Diabetes Res Clin Pract"},{"key":"10.1038\/ki.2010.292_bb0370","doi-asserted-by":"crossref","first-page":"2643","DOI":"10.1056\/NEJMoa052187","article-title":"Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes","volume":"353","author":"Nathan","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1038\/ki.2010.292_bb0375","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1056\/NEJMoa0802743","article-title":"Effects of intensive glucose lowering in type 2 diabetes","volume":"358","author":"Action to Control Cardiovascular Risk in Diabetes Study GroupGerstein","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1038\/ki.2010.292_bb0380","first-page":"271","article-title":"Hypoglycemia in the DCCT","volume":"46","author":"The DCCT Research Group","year":"1997","journal-title":"Diabetes"},{"key":"10.1038\/ki.2010.292_bb0385","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1056\/NEJM197801052980101","article-title":"Effect of weight loss without salt restriction on the reduction of blood pressure in overweight hypertensive patients","volume":"298","author":"Reisin","year":"1978","journal-title":"N Eng J Med"},{"key":"10.1038\/ki.2010.292_bb0390","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1053\/ajkd.2003.50039","article-title":"Beneficial effects of weight loss in overweight patients with chronic proteinuric nephropathies","volume":"41","author":"Morales","year":"2003","journal-title":"Am J Kidney Dis"},{"key":"10.1038\/ki.2010.292_bb0395","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1097\/01.ASN.0000068462.38661.89","article-title":"The effects of weight loss on renal function in patients with severe obesity","volume":"14","author":"Chagnac","year":"2003","journal-title":"J Am Soc Nephrol"},{"key":"10.1038\/ki.2010.292_bb0400","doi-asserted-by":"crossref","first-page":"367","DOI":"10.5694\/j.1326-5377.2006.tb00278.x","article-title":"Reversible obesity-related glomerulopathy following weight reduction","volume":"184","author":"Tran","year":"2006","journal-title":"Med J Aust"},{"key":"10.1038\/ki.2010.292_bb0405","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1681\/ASN.2006080917","article-title":"Effect of drastic weight loss after bariatric surgery on renal parameters in extremely obese patients: long-term follow-up","volume":"17","author":"Navarro-D\u00edaz","year":"2006","journal-title":"J Am Soc Nephrol"},{"key":"10.1038\/ki.2010.292_bb0410","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/j.clnu.2005.11.014","article-title":"The effect of bariatric surgery on adipocytokines, renal parameters and other cardiovascular risk factors in severe and very severe obesity: 1-year follow-up","volume":"25","author":"Serra","year":"2006","journal-title":"Clin Nutr"},{"key":"10.1038\/ki.2010.292_bb0415","unstructured":"\u2018Dietary Intake of Ten Key Nutrients for Public Health United States: 1999-2000\u2019 (Advance Data Report No. 334) http:\/\/www.cdc.gov\/nchs\/data\/ad\/ad334.pdf Accessed 8 April 2010"},{"key":"10.1038\/ki.2010.292_bb0420","doi-asserted-by":"crossref","first-page":"627","DOI":"10.7326\/0003-4819-124-7-199604010-00002","article-title":"The effect of dietary protein restriction on the progression of diabetic and nondiabetic renal diseases: a meta-analysis","volume":"124","author":"Pedrini","year":"1996","journal-title":"Ann Intern Med"},{"key":"10.1038\/ki.2010.292_bb0425","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1053\/ajkd.1998.v31.pm9631839","article-title":"A meta-analysis of the effects of dietary protein restriction on the rate of decline in renal function","volume":"31","author":"Kasiske","year":"1998","journal-title":"Am J Kidney Dis"},{"key":"10.1038\/ki.2010.292_bb0430","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1046\/j.1523-1755.2002.00421.x","article-title":"Effect of dietary protein restriction on prognosis in patients with diabetic nephropathy","volume":"62","author":"Hansen","year":"2002","journal-title":"Kidney Int"},{"key":"10.1038\/ki.2010.292_bb0435","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1056\/NEJM198209093071104","article-title":"Dietary protein intake and the progressive nature of kidney disease: the role of hemodynamically mediated glomerular injury in the pathogenesis of progressive glomerular sclerosis in aging, renal ablation, and intrinsic renal disease","volume":"307","author":"Brenner","year":"1982","journal-title":"N Engl J Med"},{"key":"10.1038\/ki.2010.292_bb0440","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.1056\/NEJM199106063242304","article-title":"Effect of strict glycemic control on renal hemodynamic response to amino acids and renal enlargement in insulin-dependent diabetes mellitus","volume":"324","author":"Tuttle","year":"1991","journal-title":"N Engl J Med"},{"key":"10.1038\/ki.2010.292_bb0445","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1046\/j.1523-1755.1999.00274.x","article-title":"Low protein diet and kidney function insulin-dependent diabetic patients with diabetic nephropathy","volume":"55","author":"Hansen","year":"1999","journal-title":"Kidney Int"},{"key":"10.1038\/ki.2010.292_bb0450","doi-asserted-by":"crossref","first-page":"F103","DOI":"10.1152\/ajprenal.00155.2001","article-title":"Effects of amino acids and glucagon on renal hemodynamics in type 1 diabetes","volume":"282","author":"Tuttle","year":"2002","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1038\/ki.2010.292_bb0455","first-page":"281","article-title":"Application of Lower Sodium Intake. Recommendations to Adults\u2014United States, 1999-2006","volume":"58","author":"Centers for Disease Controland Prevention (CDC)","year":"2009","journal-title":"MMWR"},{"key":"10.1038\/ki.2010.292_bb0460","first-page":"319","article-title":"Intersalt: an international study of electrolyte excretion and blood pressure. Results for 24h urinary sodium and potassium excretion","volume":"297","author":"Intersalt Cooperative Research Group","year":"1998","journal-title":"BMJ"},{"key":"10.1038\/ki.2010.292_bb0465","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1056\/NEJM200101043440101","article-title":"Effects on blood pressure of reduced dietary sodium and the dietary approaches to stop hypertension (DASH) diet. DASH-Sodium Collaborative Research Group","volume":"344","author":"Sacks","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1038\/ki.2010.292_bb0470","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1001\/archinte.161.5.685","article-title":"Effects of reduced sodium intake on hypertension control in older individuals. Results from the Trial of nonpharmacologic interventions in the elderly (TONE)","volume":"161","author":"Appel","year":"2001","journal-title":"Arch Int Med"},{"key":"10.1038\/ki.2010.292_bb0475","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1136\/bmj.39147.604896.55","article-title":"Long term effects of dietary sodium reduction on cardiovascular disease outcomes: observational follow-up of the trials of hypertension prevention (TOHP)","volume":"334","author":"Cook","year":"2007","journal-title":"BMJ"},{"key":"10.1038\/ki.2010.292_bb0480","unstructured":"Glucophage [package insert]. Bristol-Myers Squibb, Princeton, NJ; January 2009 http:\/\/packageinserts.bms.com\/pi\/pi_glucophage.pdf Accessed April 17 2010."},{"key":"10.1038\/ki.2010.292_bb0485","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.2146\/ajhp080330","article-title":"Metformin use in renal dysfunction: is a serum creatinine threshold appropriate?","volume":"66","author":"Philbrick","year":"2009","journal-title":"Am J Health Syst Pharm"},{"key":"10.1038\/ki.2010.292_bb0490","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1111\/j.1464-5491.2007.02221.x","article-title":"Establishing pragmatic estimated GFR thresholds to guide metformin prescribing","volume":"24","author":"Shaw","year":"2007","journal-title":"Diabet Med"},{"key":"10.1038\/ki.2010.292_bb0495","doi-asserted-by":"crossref","first-page":"e69","DOI":"10.1161\/CIRCULATIONAHA.106.179918","article-title":"Heart disease and stroke statistics\u20132007 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee","volume":"115","author":"Rosamond","year":"2007","journal-title":"Circulation"},{"key":"10.1038\/ki.2010.292_bb0500","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.ahj.2004.08.005","article-title":"Characteristics and outcomes of patients hospitalized for heart failure in the United States: rationale, design, and preliminary observations from the first 100,000 cases in the Acute Decompensated Heart Failure National Registry (ADHERE)","volume":"149","author":"Adams","year":"2005","journal-title":"Am Heart J"},{"key":"10.1038\/ki.2010.292_bb0505","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/S0002-8703(03)00189-3","article-title":"Most hospitalized older persons do not meet the enrollment criteria for clinical trials in heart failure","volume":"146","author":"Masoudi","year":"2003","journal-title":"Am Heart J"},{"key":"10.1038\/ki.2010.292_bb0510","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/j.cardfail.2007.03.011","article-title":"High prevalence of renal dysfunction and its impact on outcome in 118,465 patients hospitalized with acute decompensated heart failure: a report from the ADHERE database","volume":"13","author":"Heywood","year":"2007","journal-title":"J Card Fail"},{"key":"10.1038\/ki.2010.292_bb0515","first-page":"161","article-title":"Prevalence of chronic kidney disease and associated risk factors\u2013United States, 1999-2004","volume":"56","author":"Centers for Disease Control Prevention","year":"2007","journal-title":"MMWR"},{"key":"10.1038\/ki.2010.292_bb0520","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.hfc.2008.03.008","article-title":"Epidemiology of chronic kidney disease in heart failure","volume":"4","author":"Ahmed","year":"2008","journal-title":"Heart Fail Clin"},{"key":"10.1038\/ki.2010.292_bb0525","series-title":"USRDS 2009 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States","author":"U.S. Renal Data Systmem","year":"2009"},{"key":"10.1038\/ki.2010.292_bb0530","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.1681\/ASN.2005111200","article-title":"Racial differences in the prevalence of chronic kidney disease among participants in the Reasons for Geographic and Racial Differences in Stroke (REGARDS) Cohort Study","volume":"17","author":"McClellan","year":"2006","journal-title":"J Am Soc Nephrol"},{"key":"10.1038\/ki.2010.292_bb0535","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1093\/eurheartj\/ehi020","article-title":"The severe cardiorenal syndrome: \u2018Guyton revisited\u2019","volume":"26","author":"Bongartz","year":"2005","journal-title":"Eur Heart J"},{"key":"10.1038\/ki.2010.292_bb0540","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1007\/s10741-005-6129-4","article-title":"The cardiorenal syndrome: lessons from the ADHERE database and treatment options","volume":"9","author":"Heywood","year":"2004","journal-title":"Heart Fail Rev"},{"key":"10.1038\/ki.2010.292_bb0545","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.1161\/01.CIR.0000143547.55093.17","article-title":"The clinical challenge of cardiorenal syndrome","volume":"110","author":"Shlipak","year":"2004","journal-title":"Circulation"},{"key":"10.1038\/ki.2010.292_bb0550","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1016\/S0735-1097(00)00582-9","article-title":"Predictors of congestive heartfailure in the elderly: the Cardiovascular Health Study","volume":"35","author":"Gottdiener","year":"2000","journal-title":"J Am Coll Cardiol"},{"key":"10.1038\/ki.2010.292_bb0555","doi-asserted-by":"crossref","first-page":"2154","DOI":"10.1161\/01.CIR.0000095676.90936.80","volume":"108","author":"Sarnak","year":"2003","journal-title":"Circulation"},{"key":"10.1038\/ki.2010.292_bb0560","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1016\/S0735-1097(03)00163-3","article-title":"Renal insufficiency as a predictor of cardiovascular outcomes and mortality in elderly individuals","volume":"41","author":"Fried","year":"2003","journal-title":"J Am Coll Cardiol"},{"key":"10.1038\/ki.2010.292_bb0565","doi-asserted-by":"crossref","first-page":"237","DOI":"10.7326\/0003-4819-145-4-200608150-00003","article-title":"Cystatin C and prognosis for cardiovascular and kidney outcomes in elderly persons without chronic kidney disease","volume":"145","author":"Shlipak","year":"2006","journal-title":"Ann Intern Med"},{"key":"10.1038\/ki.2010.292_bb0570","doi-asserted-by":"crossref","first-page":"e114","DOI":"10.1161\/01.CIR.0000097492.23343.A4","article-title":"Cardiology patient page. Kidney failure and cardiovascular disease","volume":"108","author":"Abbott","year":"2003","journal-title":"Circulation"},{"key":"10.1038\/ki.2010.292_bb0575","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/j.hfc.2008.03.007","article-title":"Changes in kidney function following heart failure treatment: focus on renin-angiotensin system blockade","volume":"4","author":"Blankstein","year":"2008","journal-title":"Heart Fail Clin"},{"key":"10.1038\/ki.2010.292_bb0580","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/j.hfc.2008.03.006","article-title":"Renal hemodynamic changes in heart failure","volume":"4","author":"Blankstein","year":"2008","journal-title":"Heart Fail Clin"},{"key":"10.1038\/ki.2010.292_bb0585","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1161\/CIRCULATIONAHA.108.778811","article-title":"Serum Potassium and Clinical Outcomes in the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS)","volume":"118","author":"Pitt","year":"2008","journal-title":"Circulation"},{"key":"10.1038\/ki.2010.292_rf0590","doi-asserted-by":"crossref","first-page":"2700","DOI":"10.1161\/01.CIR.102.22.2700","article-title":"Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure: insights from the randomized aldactone evaluation study (RALES). Rales Investigators","volume":"102","author":"Zannad","year":"2000","journal-title":"Circulation"},{"key":"10.1038\/ki.2010.292_rf0595","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1161\/01.CIR.103.3.476","volume":"103","year":"2001","journal-title":"Circulation"}],"container-title":["Kidney International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0085253815546425?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0085253815546425?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2021,11,6]],"date-time":"2021-11-06T11:33:53Z","timestamp":1636198433000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0085253815546425"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,10]]},"references-count":118,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2010,10]]}},"alternative-id":["S0085253815546425"],"URL":"https:\/\/doi.org\/10.1038\/ki.2010.292","relation":{},"ISSN":["0085-2538"],"issn-type":[{"value":"0085-2538","type":"print"}],"subject":[],"published":{"date-parts":[[2010,10]]}}}